MRD-Directed Consolidation With Epcor-only or Epcor-R2 Post Anti-CD19 CAR TCell Therapy for Large B-Cell Lymphoma

This study tests additional consolidation therapy for patients with large B-cell lymphoma (a type of blood cancer) who had a partial or complete response to CAR T-cell therapy but still have detectable residual cancer in their blood (MRD-positive). Researchers are testing whether adding epcoritamab (a bispecific antibody) with or without lenalidomide and rituximab can eliminate this remaining cancer. **You may be eligible if...** - You are 16 or older with relapsed/refractory large B-cell lymphoma - You received approved CAR T-cell therapy as your most recent treatment - Your cancer showed a partial or complete response on a PET/CT scan after CAR T-cell therapy - You still have detectable cancer cells in your bloodstream (MRD-positive) on a specialized blood test - Your general health is reasonably good (ECOG 0–2) **You may NOT be eligible if...** - Your cancer did not respond to CAR T-cell therapy - You are MRD-negative (no detectable cancer in the blood) - You are under 16 years old Talk to your doctor to see if this trial is right for you.